In short
This article discusses an innovative gene therapy approach for treating X-Linked Chronic Granulomatous Disease (X-CGD). The treatment involves using autologous CD34+ cells transduced with the G1XCGD lentiviral vector containing the human CYBB gene. This phase I/II clinical trial aims to evaluate the safety and efficacy of this gene therapy in patients with X-CGD, potentially offering a new treatment option for this rare genetic disorder.
At a glance
- Trial Type
- Phase I/II, non-randomized, monocentric open-label study
- Treatment
- Autologous CD34+ cells transduced with G1XCGD lentiviral vector
- Condition
- X-linked Chronic Granulomatous Disease (X-CGD)
- Main Objective
- Evaluate safety and efficacy of gene therapy
- Primary Endpoints
- 1. Safety (adverse events incidence); 2. Efficacy (≥5% functioning neutrophils at 12 months)
- Key Eligibility
- Male X-CGD patients >23 months, severe ongoing infections, no HLA-matched donor
- Exclusion Criteria
- HLA-identical donor available, contraindications for leukapheresis or conditioning
- Secondary Objectives
- 1. Clinical efficacy against infections; 2. Transduction of CD34+ cells; 3. Evaluation of engraftment and stability
What is this treatment?
The treatment we're discussing is a complex medical procedure known as AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH THE G1XCGD LENTIVIRAL VECTOR CONTAINING THE HUMAN CYBB GENE. It's also known by the simpler name OTL-102. This is a type of gene therapy, which means it involves modifying a person's genes to treat or cure a disease.
How does it work?
This treatment works in several steps:
- Cell collection: First, doctors collect special cells called CD34+ cells from the patient's own body. These are a type of stem cell that can develop into different types of blood cells.
- Gene modification: Then, in a laboratory, these cells are modified using a tool called a lentiviral vector. This vector carries a healthy copy of the CYBB gene (also known as gp91phox) into the cells.
- Cell return: Finally, these modified cells are given back to the patient through an intravenous (IV) injection.
The goal is for these modified cells to produce healthy blood cells that can fight infections properly.
What condition does it treat?
This treatment is being developed for X-linked Chronic Granulomatous Disease (X-CGD). This is a rare genetic disorder that affects the immune system.
In X-CGD, certain immune cells called phagocytes can't effectively kill certain bacteria and fungi. This leads to severe, recurrent infections and inflammatory problems. The 'X-linked' part means it primarily affects males.
Current Clinical Trial
This treatment is currently being studied in a clinical trial. The trial is described as a "phase I/II, non-randomized, monocentric open-label study." Let's break down what this means:
- Phase I/II: This means the trial is testing both safety and how well the treatment works.
- Non-randomized: All participants receive the same treatment; there's no placebo group.
- Monocentric: The study is being conducted at a single medical center.
- Open-label: Both the researchers and participants know what treatment is being given.
Who is eligible for the trial?
The trial has specific criteria for who can participate. Here are some key points:
- Male patients with X-CGD, typically over 23 months old (younger patients may be considered in some cases)
- Patients must have a confirmed molecular diagnosis of X-CGD
- Patients must have a severe ongoing infection or be at high risk of infection despite conventional therapy
- Patients should not have an available HLA-matched donor for a bone marrow transplant
- Patients must not have HIV, hepatitis B, or hepatitis C
There are also several exclusion criteria, such as contraindications to certain procedures or medications involved in the treatment.
What are the objectives of the trial?
The main goal of this trial is to evaluate how safe and effective this treatment is. Specifically, researchers want to see if it can restore the function of certain immune cells and if this improvement lasts for at least 12 months.
Secondary objectives include:
- Evaluating clinical efficacy, particularly in improving immunity against bacterial and fungal infections
- Assessing how well the gene transfer process works
- Studying how the modified cells establish themselves and persist in the body over time
What are the endpoints of the trial?
The trial has several "endpoints" or outcomes that it will measure to determine if the treatment is successful:
- Primary endpoints:
- Safety: Measuring any adverse events related to the treatment
- Efficacy: Checking if at least 5% of certain immune cells (granulocytes) are functioning correctly after 12 months
- Secondary endpoints:
- Improvements in nutritional status, growth, and development
- Clearing of pre-existing infections or inflammatory problems
- Measuring the percentage of modified cells in the blood over time
- Assessing overall improvements in immune function and ability to fight infections
This trial represents an important step in developing a potential new treatment for X-linked Chronic Granulomatous Disease, a serious genetic disorder affecting the immune system.